AVR 0.00% $13.14 anteris technologies ltd

cardiocel paper, page-3

  1. 1,498 Posts.
    lightbulb Created with Sketch. 94

    Frazer front:

    J. Immunother., 2017 vol. 40(2) pp. 62-70
    DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection
    Chandra, J; Dutton, JL; Li, B; Woo, WP; Xu, Y; Tolley, LK; Yong, M; Wells, JW; R Leggatt, G; Finlayson, N; Frazer, IH
    We have previously shown that a novel DNA vaccine technology of codon optimization and the addition of ubiquitin sequences enhanced immunogenicity of a herpes simplex virus 2 polynucleotide vaccine in mice, and induced cell-mediated immunity when administered in humans at relatively low doses of naked DNA. We here show that a new polynucleotide vaccine using the same technology and encoding a fusion protein of the E6 and E7 oncogenes of high-risk human papillomavirus type 16 (HPV16) is immunogenic in mice. This vaccine induces long-lasting humoral and cell-mediated immunity and protects mice from establishment of HPV16-E7-expressing tumors. In addition, it suppresses growth of readily established tumors and shows enhanced efficacy when combined with immune checkpoint blockade targeted at PD-L1. This vaccine also facilitates rejection of HPV16-E7-expressing skin grafts that demonstrate epidermal hyperplasia with characteristics of cervical and vulvar intraepithelial neoplasia. Clinical studies evaluating the efficacy of this vaccine in patients with HPV16 premalignancies are planned.
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
(20min delay)
Last
$13.14
Change
0.000(0.00%)
Mkt cap ! $277.7M
Open High Low Value Volume
$13.33 $13.91 $13.14 $302.2K 22.46K

Buyers (Bids)

No. Vol. Price($)
1 299 $13.14
 

Sellers (Offers)

Price($) Vol. No.
$13.49 35 1
View Market Depth
Last trade - 16.10pm 13/09/2024 (20 minute delay) ?
AVR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.